International Journal of Pediatrics and Genetics
Vol. 3 No. 3 (2025)
ISSN: 2995-5483

Type 2 Diabetes Mellitus: Pathophysiology, Management, and Future Directions

Zulfkar Qadrie
Department of Pharmacology, Government Medical College Baramulla

Humaira Ashraf
Department of Animal Nutrition, SKUAST-K, Srinagar, India

Mohd Altaf Dar
Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab

Afshana Qadir
Nursing Tutor, Government College of Nursing Baramulla

Abstract: Type 2 Diabetes Mellitus (T2DM) is a prevalent and escalating chronic metabolic disorder, affecting millions globally. It is characterized by a combination of insulin resistance, where the body's cells fail to respond adequately to insulin, and impaired insulin secretion, which leads to chronically elevated blood glucose levels. Over time, this dysregulation of glucose metabolism results in a variety of complications, including cardiovascular disease, kidney failure, neuropathy, and retinopathy, significantly contributing to morbidity and mortality worldwide. The pathophysiology of T2DM involves complex genetic, environmental, and lifestyle factors. Obesity, physical inactivity, poor dietary habits, and family history are some of the key risk factors. As the disease progresses, beta-cell dysfunction in the pancreas further exacerbates insulin secretion issues. Clinically, T2DM is often asymptomatic in its early stages, but common manifestations include polyuria, polydipsia, and fatigue. Diagnosis is typically confirmed through blood tests, including fasting blood glucose levels and HbA1c tests. Management of T2DM is multifaceted, including lifestyle modifications such as weight management, regular physical activity, and dietary changes. Pharmacologic interventions, such as metformin, sulfonylureas, and insulin therapy, are common, though emerging therapies such as GLP-1 receptor agonists, SGLT2 inhibitors, and personalized medicine approaches are gaining prominence. Additionally, technological advancements, like continuous glucose monitoring and artificial pancreas systems, are revolutionizing diabetes care. Future research is focusing on novel therapies aimed at restoring beta-cell function, gene therapy, and precision medicine tailored to individual patient profiles. These innovations promise improved outcomes and a more effective management paradigm for T2DM.

Key words: Insulin Resistance, Hyperglycemia, Risk Factors, Management, Personalized Medicine

1. Introduction

Type 2 Diabetes Mellitus (T2DM) is one of the most prevalent and rapidly growing chronic diseases worldwide. Its increasing incidence is largely attributed to several factors, including the aging population, sedentary lifestyles, poor dietary habits, and genetic predisposition. As a significant global health concern, T2DM not only contributes to considerable morbidity and mortality but also

Vol. 3 No. 3 (2025)
ISSN: 2995-5483

imposes a substantial economic burden on healthcare systems. The condition is characterized by insulin resistance and relative insulin deficiency, which leads to chronic hyperglycemia, the hallmark of the disease. Over time, this persistent elevation in blood glucose levels causes a range of complications that affect multiple organ systems, such as the cardiovascular, renal, nervous, and ocular systems. Unlike Type 1 diabetes, which is primarily caused by the autoimmune destruction of insulin-producing pancreatic β-cells, T2DM involves a complex interplay of genetic, environmental, and lifestyle factors [1]. In T2DM, the body's cells become resistant to the effects of insulin, a hormone responsible for promoting glucose uptake into cells. As a result, the pancreas compensates by producing more insulin in an attempt to overcome the resistance. However, over time, the pancreatic β-cells become exhausted, leading to a relative insulin deficiency. This combination of insulin resistance and insufficient insulin secretion contributes to elevated blood glucose levels, which are sustained over time, resulting in hyperglycemia. The pathophysiology of T2DM is multifactorial. Genetic predisposition plays a significant role in the development of the disease, with a family history of diabetes being one of the strongest risk factors. However, lifestyle factors are also critical in the disease's onset and progression [2]. Poor dietary habits, such as excessive consumption of refined carbohydrates, sugars, and fats, combined with physical inactivity, contribute to obesity, which is one of the most important modifiable risk factors for T2DM. Adiposity, especially visceral fat accumulation, further exacerbates insulin resistance by secreting inflammatory cytokines and hormones that interfere with the normal action of insulin. Obesity is a central player in the development of T2DM. It leads to increased free fatty acids, which impair insulin action, and it disrupts the function of adipokines, hormones produced by adipose tissue that regulate insulin sensitivity. As obesity rates continue to rise globally, particularly in developed nations, the prevalence of T2DM is also increasing. Other environmental factors, such as stress, sleep deprivation, and certain medications, also contribute to the development of T2DM. Clinically, T2DM often develops insidiously, and many individuals may be asymptomatic or present with vague symptoms for years before being diagnosed. Common symptoms include polyuria (frequent urination), polydipsia (excessive thirst), unexplained weight loss, and fatigue. However, by the time symptoms appear, significant damage to organs and tissues may have already occurred. Therefore, early detection is crucial in preventing or delaying the onset of complications [3].

The diagnostic criteria for T2DM include elevated fasting blood glucose levels (≥126 mg/dL), a 2-hour postprandial glucose level of ≥200 mg/dL during an oral glucose tolerance test, or an HbA1c level of ≥6.5%. Screening for T2DM is recommended for individuals over 45 years of age, or earlier for those with risk factors such as obesity, a family history of diabetes, or hypertension. Management of T2DM is multifaceted, involving both lifestyle modifications and pharmacologic interventions. Lifestyle changes are the cornerstone of diabetes management, and these include weight reduction, regular physical activity, and dietary adjustments. A diet rich in whole grains, vegetables, lean proteins, and healthy fats, along with the reduction of refined sugars and processed foods, is recommended [4]. Regular physical activity helps improve insulin sensitivity, reduces weight, and lowers blood glucose levels. Patients are also advised to monitor their blood glucose levels regularly to assess the effectiveness of their management strategies. Pharmacologically, a variety of medications are used to manage T2DM, and the choice of treatment depends on factors such as the degree of hyperglycemia, the presence of comorbidities, and patient preferences. Metformin, an insulin sensitizer, is typically the first-line treatment for most individuals with T2DM. Other medications, such as sulfonylureas, thiazolidinediones, and GLP-1 receptor agonists, may be added depending on the patient's specific needs. In more advanced cases, insulin therapy may be required. Emerging therapies, including SGLT2 inhibitors, DPP-4 inhibitors, and the use of GLP-1 receptor agonists, are gaining popularity due to their ability to improve glycemic control, reduce cardiovascular risk, and promote weight loss [5]. Additionally, the advent of continuous glucose monitoring (CGM) systems and insulin pumps has revolutionized the management of T2DM by providing real-time data on glucose levels, enabling more precise adjustments in treatment. The complications of T2DM are extensive and can affect virtually every organ system. Cardiovascular

Vol. 3 No. 3 (2025)
ISSN: 2995-5483

disease is one of the leading causes of death in individuals with T2DM, as hyperglycemia accelerates atherosclerosis and increases the risk of heart attack and stroke. Diabetic nephropathy, or kidney disease, is another major complication, as high blood glucose levels damage the kidneys over time. Neuropathy, characterized by nerve damage, and retinopathy, leading to vision loss, are also common in individuals with poorly controlled diabetes [6].

2. Pathophysiology of Type 2 Diabetes Mellitus

The pathophysiology of Type 2 Diabetes Mellitus (T2DM) is multifactorial, involving interplay of genetic, environmental, and lifestyle factors that lead to the development and progression of the disease. A key feature of T2DM is insulin resistance, where tissues such as skeletal muscle, liver, and adipose tissue become less responsive to the effects of insulin. Under normal conditions, insulin facilitates the uptake of glucose into cells, enabling energy production. However, in T2DM, the insulin signaling pathway is disrupted, causing tissues to fail to respond adequately to insulin. As a result, glucose uptake is impaired, and circulating glucose levels rise. In response to insulin resistance, the pancreas attempts to compensate by increasing insulin production [7]. However, over time, the pancreatic β-cells, which are responsible for insulin secretion, become dysfunctional and eventually fail to secrete adequate amounts of insulin. This β-cell dysfunction further exacerbates the problem, as insulin production cannot keep pace with the body's needs, leading to relative insulin deficiency. The combination of insulin resistance and β-cell dysfunction results in elevated blood glucose levels, which is a defining characteristic of T2DM. Over time, this chronic hyperglycemia can lead to various complications, including cardiovascular disease, kidney dysfunction, neuropathy, and retinopathy. While genetic factors contribute to the predisposition to insulin resistance and β-cell dysfunction, environmental factors, including poor diet, physical inactivity, and obesity, significantly exacerbate the risk of developing T2DM [8].

2.1 Insulin Resistance and β-cell Dysfunction

Insulin resistance occurs when the body's tissues, such as muscle, liver, and adipose tissue, become less responsive to insulin, a hormone that plays a crucial role in regulating blood glucose levels. Under normal circumstances, insulin binds to receptors on cell surfaces, triggering glucose uptake and promoting energy storage. However, in individuals with insulin resistance, this process is impaired. As a result, glucose is not efficiently taken up by the cells, leading to elevated blood glucose levels, or hyperglycemia. To compensate for this reduced sensitivity, the pancreas increases insulin production in an attempt to maintain normal blood glucose levels. Initially, this compensatory mechanism is effective, and insulin levels in the blood rise, often significantly higher than normal. Despite this increase, glucose levels remain elevated because the cells are not adequately responding to the insulin. Over time, the continuous overproduction of insulin puts additional strain on the pancreatic β-cells, which are responsible for insulin secretion [9]. Chronic hyperinsulinemia (high levels of insulin in the blood) eventually leads to β-cell dysfunction, where the cells become exhausted and are no longer able to produce sufficient insulin. As a result, insulin secretion becomes impaired, further exacerbating the problem of elevated blood glucose levels. This progression from insulin resistance to β-cell exhaustion and impaired insulin secretion is a key characteristic of Type 2 Diabetes Mellitus (T2DM). The failure to maintain glucose homeostasis leads to chronic hyperglycemia, which, if left untreated, can result in a range of complications, including cardiovascular disease, kidney damage, and neuropathy [10].

2.2 Genetic and Environmental Factors

Genetic predisposition is an important factor in the development of Type 2 Diabetes Mellitus (T2DM), as individuals with a family history of the disease are at a higher risk of developing it themselves. Several genes have been identified that influence insulin resistance, β-cell function, and glucose metabolism, which are central to the pathophysiology of T2DM. For instance, variations in genes related to insulin secretion, pancreatic function, and adipose tissue regulation can increase susceptibility to the disease. Despite the strong genetic component, environmental factors such as obesity, physical inactivity, and poor dietary choices play a crucial role in accelerating the onset and progression of T2DM. Obesity, particularly visceral fat accumulation, is one of the most significant modifiable risk factors for T2DM. Excess body fat, especially around the abdomen, contributes to insulin resistance by releasing free fatty acids and inflammatory cytokines that impair the normal functioning of insulin in the body [11]. These factors reduce the ability of insulin to facilitate glucose uptake into cells, leading to higher blood glucose levels. Additionally, obesity disrupts the function of adipokines, hormones produced by fat cells that are involved in regulating insulin sensitivity and glucose homeostasis. Physical inactivity is another key risk factor for T2DM. Regular exercise improves insulin sensitivity, reduces body fat, and enhances glucose uptake by muscle cells. Lack of physical activity, particularly in combination with poor diet, promotes weight gain and further exacerbates insulin resistance. Inactive individuals are more likely to develop T2DM, as their bodies cannot effectively manage glucose levels. Poor dietary choices, particularly the consumption of high amounts of refined carbohydrates, sugars, and unhealthy fats, contribute to both obesity and insulin resistance. Diets rich in processed foods and high in caloric intake can overwhelm the body's ability to regulate blood glucose levels, significantly increasing the risk of developing T2DM [12].

3. Risk Factors for Type 2 Diabetes Mellitus

Key risk factors for developing Type 2 Diabetes Mellitus (T2DM) are influenced by both genetic and environmental factors. One of the most significant risk factors is obesity, particularly central or visceral obesity, which is strongly associated with insulin resistance. Visceral fat, located around internal organs, releases inflammatory substances and free fatty acids that interfere with the body’s ability to respond to insulin. As insulin resistance worsens, the pancreas compensates by producing more insulin, but eventually, this can lead to β-cell dysfunction and impaired insulin secretion, contributing to the development of T2DM. Age is another important factor, with the incidence of T2DM increasing significantly in individuals over the age of 45 [13]. This is partly due to the natural decline in insulin sensitivity that occurs with aging. Additionally, the cumulative effect of lifestyle factors such as diet and physical activity becomes more prominent as individuals grow older. Family history also plays a critical role, as a family history of diabetes can increase an individual’s risk of developing T2DM due to shared genetic predispositions that affect insulin sensitivity and glucose metabolism. Physical inactivity is another key contributor to T2DM. Regular exercise improves insulin sensitivity and helps control body weight, while lack of physical activity contributes to obesity and worsens insulin resistance. Similarly, poor dietary habits, particularly diets high in processed foods, sugars, and unhealthy fats, contribute significantly to the risk of developing T2DM. These dietary factors promote weight gain and insulin resistance. Finally, ethnicity is a notable risk factor, with certain populations, including African American, Hispanic, and Native American groups, having a higher predisposition to T2DM due to genetic and environmental factors [14].

4. Clinical Manifestations and Diagnosis

The symptoms of Type 2 Diabetes Mellitus (T2DM) develop gradually and may include polyuria (frequent urination), polydipsia (excessive thirst), blurred vision, fatigue, and unexplained weight loss. However, many individuals may remain asymptomatic for years, making early detection challenging. As a result, by the time symptoms become noticeable, significant damage to organs and tissues may have already occurred. This highlights the importance of early screening, especially for those at higher risk, such as individuals with obesity, a family history of diabetes, or older age. Early intervention can help prevent or delay the onset of complications [15].

4.1 Diagnostic Criteria

The diagnosis of Type 2 Diabetes Mellitus (T2DM) is based on several diagnostic criteria that assess blood glucose levels. One of the primary tests is the Fasting Plasma Glucose (FPG) test, where a level of ≥ 126 mg/dL (7.0 mmol/L) after an overnight fast indicates diabetes. Another key test is the Oral Glucose Tolerance Test (OGTT), where a 2-hour plasma glucose level of ≥ 200 mg/dL (11.1 mmol/L) confirms the diagnosis. Additionally, the Hemoglobin A1c test is used to measure average blood glucose levels over the past two to three months, with a value of ≥ 6.5% suggesting T2DM. Lastly, a Random Plasma Glucose test can be used, where a glucose level of ≥ 200 mg/dL, along with symptoms of hyperglycemia such as polyuria, polydipsia, or fatigue, can confirm the presence of diabetes. These tests help to identify individuals with elevated blood glucose levels and enable early intervention to manage the disease, preventing the progression to more severe complications. Early diagnosis and monitoring are essential in controlling the disease and improving long-term health outcomes for individuals with T2DM [16].

5. Management of Type 2 Diabetes Mellitus

Effective management of Type 2 Diabetes Mellitus (T2DM) requires a comprehensive approach that includes lifestyle changes, such as a balanced diet, regular exercise, and weight management. Pharmacologic treatment, like insulin or oral medications, helps control blood glucose levels. Additionally, regular monitoring of glucose levels ensures timely adjustments to treatment strategies [17].

5.1 Lifestyle Modifications

Lifestyle changes are considered the cornerstone of managing Type 2 Diabetes Mellitus (T2DM). One of the most important aspects is dietary modifications, which focus on a balanced diet that helps manage calorie intake. Reducing the consumption of refined sugars, processed foods, and unhealthy fats is key to controlling blood glucose levels and preventing further weight gain. Emphasizing whole grains, lean proteins, vegetables, and healthy fats ensures that blood glucose levels remain stable and that essential nutrients are provided to the body.Physical activity is another vital component of T2DM management. Regular exercise, including aerobic activities and resistance training, enhances insulin sensitivity, allowing the body to use insulin more effectively [18]. Exercise also helps control blood sugar levels and promotes overall health. In addition to improving insulin sensitivity, physical activity aids in weight control, which is critical in managing T2DM. Weight loss plays a significant role in improving blood glucose control. Even modest weight loss, typically around 5-10% of total body weight, can lead to significant improvements in insulin sensitivity and glycemic control. This reduction in body fat also reduces the need for medications in some individuals, further highlighting the importance of weight management in managing T2DM. Together, these lifestyle changes provide a holistic approach to managing T2DM, improving long-term outcomes and quality of life [19].

5.2 Pharmacologic Treatments

Several classes of medications are used in the management of Type 2 Diabetes Mellitus (T2DM), each targeting different mechanisms to help control blood glucose levels. **Metformin** is typically the first-line therapy for T2DM. It works primarily by reducing hepatic glucose production, thereby lowering blood glucose levels. Metformin also improves insulin sensitivity in muscle and fat tissue, which further aids in glucose control. **Sulfonylureas** are another class of medications that stimulate insulin secretion from the pancreas. By increasing insulin release, sulfonylureas help to reduce blood glucose levels, although their effectiveness can decrease over time as β-cell function declines [20]. **GLP-1 Receptor Agonists** are a newer class of drugs that enhance insulin secretion in response to meals, while also inhibiting glucagon release and slowing gastric emptying. These medications not only improve blood glucose control but also promote weight loss, which is beneficial for managing T2DM, especially in overweight or obese individuals. **SGLT2 Inhibitors** work by preventing the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. This helps lower blood glucose levels and may also provide additional benefits, such as reducing the risk of heart failure and kidney disease. In some cases, **insulin therapy** may be necessary when other medications are not sufficient to control blood glucose levels. Insulin is used to supplement the body’s natural insulin production, especially when β-cell dysfunction is significant. Together, these medications help manage T2DM effectively, addressing various aspects of glucose metabolism [21].

5.3 Emerging Therapies

GLP-1 Receptor Agonists and **SGLT2 Inhibitors** are gaining popularity in the management of Type 2 Diabetes Mellitus (T2DM) due to their multifaceted benefits beyond simply controlling blood glucose levels. GLP-1 Receptor Agonists, such as liraglutide and semaglutide, work by enhancing insulin secretion in response to meals, inhibiting glucagon release, and slowing gastric emptying. These effects not only improve glycemic control but also contribute to weight loss, which is particularly beneficial for obese individuals with T2DM. Weight loss helps reduce insulin resistance, making it easier to manage blood sugar levels [22]. Furthermore, GLP-1 Receptor Agonists have been shown to reduce cardiovascular risk, including the risk of heart attack and stroke, making them a valuable option for T2DM patients with a high risk of cardiovascular disease. Similarly, **SGLT2 Inhibitors** such as empagliflozin and canagliflozin prevent the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine. In addition to improving blood glucose control, SGLT2 Inhibitors offer cardiovascular protection by reducing the risk of heart failure and stroke. They also provide renal protection by reducing the progression of diabetic nephropathy, a common complication of T2DM that can lead to kidney failure. In parallel, **gene therapy** and **immunotherapy** are areas of ongoing research aimed at improving insulin sensitivity and β-cell function. Gene therapy aims to correct underlying genetic defects that contribute to insulin resistance, while immunotherapy seeks to modulate the immune system to improve β-cell survival and function. These innovative approaches hold the potential for long-term, more effective treatments that could revolutionize T2DM management [23-25].

6. Complications of Type 2 Diabetes Mellitus

Uncontrolled Type 2 Diabetes Mellitus (T2DM) can lead to a range of serious complications that affect various organ systems, making effective management critical in preventing long-term damage. One of the most significant complications is **cardiovascular disease**, as T2DM increases the risk of heart disease, stroke, and peripheral arterial disease. Chronic hyperglycemia accelerates atherosclerosis, the buildup of plaque in the arteries, leading to narrowed and hardened blood vessels. This increases the likelihood of heart attacks, strokes, and poor circulation, all of which are major contributors to morbidity and mortality in people with T2DM [26-28]. Another serious complication of uncontrolled diabetes is **retinopathy,** which occurs when chronic high blood sugar damages the blood vessels in the retina. Over time, this can impair vision and, in severe cases, lead to blindness. Diabetic retinopathy is one of the leading causes of blindness among adults, making regular eye exams essential for early detection and intervention. **Nephropathy**, or diabetic kidney disease, is another common complication of T2DM. High blood sugar levels damage the small blood vessels in the kidneys, impairing their ability to filter waste products from the blood. As the disease progresses, it can lead to kidney failure, requiring dialysis or a kidney transplant. Diabetic nephropathy is a leading cause of end-stage renal disease, making early management of blood glucose levels crucial for kidney health. Lastly, **neuropathy**, or nerve damage, is another common complication of uncontrolled T2DM. High blood glucose levels can damage nerves, particularly in the feet and legs, leading to symptoms such as numbness, tingling, pain, and even the loss of sensation. This can increase the risk of infections, ulcers, and amputations if left untreated. Early intervention and consistent blood sugar control are essential in preventing these debilitating complications [28-30].

7. Future Directions

Advancements in **personalized medicine** are set to significantly improve outcomes for patients with Type 2 Diabetes Mellitus (T2DM) by tailoring treatment approaches based on individual genetic, environmental, and lifestyle factors. One promising development in personalized medicine is **genetic testing**, which can help identify genetic variants that influence how individuals respond to different medications, insulin therapies, and lifestyle changes. By understanding these genetic predispositions, healthcare providers can design more effective, targeted treatment regimens that optimize glycemic control and minimize side effects. This approach is expected to move away from the one-size-fits-all model and allow for more precise, patient-centered care. In addition to genetic testing,

individualized therapeutic regimens are also gaining traction in diabetes management [30-32]. With a better understanding of a patient's unique metabolic profile, healthcare providers can choose medications and therapies that are most likely to be effective. For instance, medications like GLP-1 receptor agonists or SGLT2 inhibitors may be prioritized based on a patient's comorbidities, such as cardiovascular disease or kidney dysfunction, ensuring a comprehensive approach to treatment. This precision in therapy, coupled with close monitoring, could significantly improve long-term management and reduce complications. Technological innovations are also transforming diabetes care [33-35]. **Continuous glucose monitoring (CGM)** systems, which provide real-time feedback on glucose levels throughout the day, are becoming increasingly accessible and affordable. CGM allows for more precise adjustments in insulin doses, reducing the risk of hyperglycemia or hypoglycemia. Additionally, **artificial pancreas systems**, which integrate insulin pumps with CGM technology, are revolutionizing disease management by automatically adjusting insulin delivery to maintain target glucose levels. These technologies, combined with personalized treatment plans, are poised to significantly enhance T2DM management, improve patient outcomes, and reduce the long-term burden of complications [35-40].

8. Conclusion

Type 2 Diabetes Mellitus (T2DM) remains a significant global health challenge, affecting millions of people worldwide and contributing to substantial morbidity, mortality, and economic burden. While current treatment strategies, including lifestyle modifications and pharmacologic interventions, effectively manage blood glucose levels and help prevent complications, the increasing prevalence of the disease highlights the need for more comprehensive solutions. Despite the availability of medications such as metformin, insulin, and newer agents like GLP-1 receptor agonists and SGLT2 inhibitors, these treatments often focus on controlling symptoms rather than addressing the underlying pathophysiology of the disease. To better manage and ultimately reduce the burden of T2DM, further research into its pathophysiology is crucial. A deeper understanding of the genetic, molecular, and cellular mechanisms that contribute to insulin resistance and β-cell dysfunction will provide insights into potential novel therapies. Additionally, research into innovative treatment modalities such as gene therapy, immunotherapy, and cellular-based therapies holds promise for improving insulin sensitivity and restoring normal β-cell function, offering the possibility of more durable solutions. Preventive strategies are equally important in addressing the rising global incidence of T2DM. Lifestyle interventions such as weight management, physical activity, and dietary changes remain fundamental, but the development of predictive tools and early intervention strategies could help identify at-risk individuals before the onset of clinical symptoms. Looking toward the future, **personalized medicine** and **precision therapies** offer the most promise in the management of T2DM. Tailoring treatments based on an individual's genetic makeup, metabolic profile, and lifestyle factors will allow for more effective and targeted interventions. This approach aims not only to improve glucose control but also to reduce complications and improve long-term outcomes, providing a more holistic and patient-centered approach to managing T2DM.

9. References

1. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. International journal of adolescent medicine and health. 2021 Jul 22;34(2):1-9.
2. Lihite RJ, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M, Phukan S. A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alexandria journal of medicine. 2017 Jul 11;53(2):151-6.
3. Zehravi M, Maqbool M, Ara I. Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview. International Journal of Adolescent Medicine and Health. 2021 Jun 18;33(6):339-45.
4. Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer: Targets and Therapy. 2022 Jan 11:15-24

5. Rasool S, Maqbool M. An overview about Hedychium spicatum: a review. Journal of Drug Delivery and Therapeutics. 2019 Feb 15;9(1-s):476-80.
6. Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):367-73.
7. Maqbool M, Gani I, Dar MA. Anti-diabetic effects of some medicinal plants in experimental animals: a review. Asian Journal of Pharmaceutical Research and Development. 2019 Feb 15;7(1):66-9.
8. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and reproductive health of women: a curious association. International journal of adolescent medicine and health. 2021 Apr 21;33(6):333-7.
9. Mohd M, Maqbool M, Dar MA, Mushtaq I. Polycystic ovary syndrome, a modern epidemic: an overview. Journal of Drug Delivery and Therapeutics. 2019 May 15;9(3):641-4.
10. Maqbool M, Fekadu G, Jiang X, Bekele F, Tolossa T, Turi E, Fetensa G, Fanta K. An up to date on clinical prospects and management of osteoarthritis. Annals of Medicine and Surgery. 2021 Dec 1;72:103077.
11. Majeed A, Bashir R, Farooq S, Maqbool M. Preparation, characterization and applications of nanoemulsions: An insight. Journal of Drug Delivery and Therapeutics. 2019 Mar 15;9(2):520-7.
12. Zehravi M, Maqbool M, Ara I. Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review. Open Health. 2022 May 2;3(1):60-5.
13. Maqbool R, Maqbool M, Zehravi M, Ara I. Menstrual distress in females of reproductive age: a literature review. International journal of adolescent medicine and health. 2021 Jul 22;34(2):11-7.
14. Ara I, Maqbool M, Fekadu G, Hajam TA, Dar MA. Pharmaceutical significance of Nigella sativa L., a wonder herb. Journal of Applied Pharmaceutical Sciences and Research. 2020;3(4):04-13.
15. Maqbool M, Nasir N, Mustafa S. Polycystic in ovarian syndrome and its various treatment strategies. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2018 Sep 1;5(9):8470-8.
16. Maqbool M, Zehravi M, Maqbool R, Ara I. Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital, Srinagar, Jammu & Kashmir, India. CELLMED. 2021;11(2):8-1.
17. Ara I, Maqbool M, Bukhari B, Ara N, Hajam TA. Present status, standardization and safety issues with herbal drugs. International Journal of Research in Pharmaceutical Sciences and Technology. 2020 May 18;1(3):95-101.
18. Ara I, Maqbool M, Gani I. Reproductive Health of Women: implications and attributes. International Journal of Current Research in Physiology and Pharmacology. 2022 Nov 28:8-18.
19. Zehravi M, Maqbool R, Maqbool M, Ara I. To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India. Journal of Pharmaceutical Research International. 2021 Jun 10;33(31A):135-40.
20. Maqbool M, Javed S, Bajwa AA. Assessment OF pain management IN postoperative cases using different scales and questionnaires. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2019 Jan 1;6(1):983-7.
21. Ara I, Maqbool M, Zehravi M. Psychic consequences of infertility on couples: A short commentary. Open Health. 2022 Jan 1;3(1):114-9.

22. Bashir R, Maqbool M, Ara I, Zehravi M. An In sight into Novel Drug Delivery System: In Situ Gels. CELLMED. 2021;11(1):6-1.
23. Zehravi M, Maqbool M, Ara I. Teenage menstrual dysfunction: an overview. International Journal of Adolescent Medicine and Health. 2022 Sep 19;35(1):15-9.
24. Ara I, Zehravi M, Maqbool M, Gani I. A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries. Journal of Pharmaceutical Research & Reports. SRC/JPRSR-131. DOI: doi. org/10.47363/JPRSR/2022 (3). 2022;127.
25. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. Indo American Journal Of Pharmaceutical Sciences. 2018 Aug 1;5(8):8254-9.
26. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8163-+.
27. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8070-6.
28. Maqbool M, Ikram U, Anwar A. Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders. Indo American Journal Of Pharmaceutical Sciences. 2018 Aug 1;5(8):8060-5.
29. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):357-66.
30. Zehravi M, Maqbool M, Ara I. An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India. The Indian Journal of Nutrition and Dietetics. 2021 Jul:408-18.
31. Maqbool M, Zehravi M. Neuroprotective role of polyphenols in treatment of neurological disorders: A review. Interventional Pain Medicine and Neuromodulation. 2021 Dec 31;1(1).
32. Maqbool M, Ara I, Gani I. The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age. International Journal of Current Research in Physiology and Pharmacology. 2022 Nov 28:19-31.
33. Maqbool M, Gani I. Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review. Journal of Pharmacy Practice and Community Medicine. 2018;4(4).
34. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. International Journal of Adolescent Medicine and Health. 2021 Aug 23;33(6):357-66.
35. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8070-6.
36. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. Indo American Journal of Pharmaceutical Sciences. 2018 Aug 1;5(8):8163-+.
37. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. Indo American Journal Of Pharmaceutical Sciences. 2018 Aug 1;5(8):8254-9.
38. Qadrie Z, Maqbool M, Dar MA, Qadir A. Navigating challenges and maximizing potential: Handling complications and constraints in minimally invasive surgery. Open Health. 2025 Feb 5;6(1):20250059.

Vol. 3 No. 3 (2025)
ISSN: 2995-5483

39. Oral O, Maqbool M, Thapa P, Tatlibal P, Enser M. The potential impact of weight control management on metabolic health during healthy aging. Global Translational Medicine. 2025 Jan 13:4815.

40. Maqbool M, Oral O. Implications of hypothyroidism in females of reproductive age: a review of current literature.